Home 2023
Yearly Archives: 2023
News
AstraZeneca enters license agreement with Alteogen for subcutaneous formulations of oncology assets
AstraZeneca and Alteogen have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform technology.
Under the terms of the agreement,...
AstraZeneca to acquire EsoBiotec in $1bn deal
AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical...
SKYCLARYS approved by Health Canada for Friedreich’s ataxia
Health Canada has approved Biogen's SKYCLARYS (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in patients 16 years of age and older. This approval...
